ClinicalTrials.gg
Active, not recruitingNCT04416568Updated Oct 20, 2026Results posted

Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers

A Phase 2 interventional study of Nivolumab and Ipilimumab in Malignant Rhabdoid Tumor, Rhabdoid Tumor of the Kidney and Epithelioid Sarcoma, sponsored by Dana-Farber Cancer Institute. Active, not recruiting at 8 sites in United States. Open to participants aged 6 Months to 40 Years. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Dana-Farber Cancer Institute · Phase 2, Interventional, and Treatment

How we know · 5 judgments

Updated Oct 20, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
6 Months to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 103 studies in Rhabdoid Tumor with a site in United States — 18 open to participants now, 39 under way, none of them phase 3. Rhabdoid Tumor · United States.

Enrollment
42nd of 92
30 · median 28
Started
2020
with 7 others
Phase 2
28 of 103
3 open now
Primary completion
2025-07
later than 11 of 38 live
Registered
77th of 103
by date
Lead sponsor
3 of 103
Dana-Farber Cancer Institute

Among the 103 studies in Rhabdoid Tumor with a site in United States, this one is the 42nd largest by enrollment of the 92 interventional ones that give a count, is one of 8 that started in 2020, is one of 28 in phase 2, reaches primary completion later than 11 of the 38 other live ones, and was the 77th registered.

Rhabdoid Tumor

115 studies on the registry are indexed under Rhabdoid Tumor; 23 are open to participants now.

Browse Rhabdoid Tumor studies →

Open to participants now

18 of the 103 studies in Rhabdoid Tumor with a site in United States are open now. Recruiting first, the newest first:

13 more — sign in →

All 18 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 20 Rhabdoid Tumor studies recruiting now, 2 (10%) set no upper age limit and 18 (90%) stop at 75 or younger; 20 take children under 18; none take healthy volunteers.

This study: 6 Months to 40 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 103 studies in Rhabdoid Tumor with a site in United States, or all of them as a file.
02

Study summary

This clinical trial is studying two immunotherapy drugs (nivolumab and ipilimumab) given together as a possible treatment for INI1-negative tumors.

Read the detailed description

This research study is a Phase II clinical trial, which tests the safety and effectiveness of an investigational drug or drug combination to learn whether the drug or drug combination works in treating a specific disease. "Investigational" means that the drug combination is being studied.

The names of the study drugs involved in this study are:

  • Nivolumab (OPDIVO)
  • Ipilimumab (YERYOY)

This trial is studying whether nivolumab and ipilimumab work to treat INI1-negative cancers.

The U.S. Food and Drug Administration (FDA) has not approved combination nivolumab and ipilimumab for the specific diseases in this study but it has been approved for other diseases. Nivolumab and ipilimumab have been tested in children to find out a safe dose of this combination.

03

Conditions studied

  • Malignant Rhabdoid Tumor
  • Rhabdoid Tumor of the Kidney
  • Epithelioid Sarcoma
  • Chordoma (Poorly Differentiated or De-differentiated)
  • Atypical Teratoid/Rhabdoid Tumor
  • Other INI1 Negative Tumors (With PI Approval)
  • Other SMARCA4-deficient Malignant Tumors (With PI Approval)

Keywords

  • Malignant Rhabdoid Tumor
  • Rhabdoid Tumor of the Kidney
  • Epithelioid Sarcoma
  • Chordoma (poorly differentiated or de-differentiated)
  • Atypical Teratoid/Rhabdoid Tumor
  • INI1 negative tumors
  • SMARCA4-deficient malignant tumors
04

Who can participate

Ages eligible
6 Months to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All participants must have one of the following confirmed tumors at original diagnosis or relapse:

    • Stratum 1

      • Malignant rhabdoid tumor (MRT)
      • Rhabdoid tumor of the kidney (RTK)
      • Epithelioid sarcoma
      • Chordoma (poorly differentiated or de-differentiated)
      • Other INI1-negative or SMARCA4-deficient malignant tumors (with PI approval)
    • Stratum 2

      • Atypical teratoid rhabdoid tumor (ATRT)
      • Other INI1-negative or SMARCA4-deficient primary CNS malignant tumors (with PI approval)
  • All participants must have tumor assessment at original diagnosis or relapse showing the following:

    • Loss of INI1 confirmed by immunohistochemistry (IHC), OR
    • Molecular confirmation of tumor bi-allelic SMARCB1 (INI1) loss or mutation when INI1 IHC is equivocal or unavailable
    • Loss of SMARCA4 confirmed by IHC or molecular confirmation of tumor bi-allelic SMARCA4 loss or mutation when SMARCA4 is equivocal or unavailable
  • disease and no standard treatment options as determined by locally or regionally available standards of care and treating physician's discretion
  • as defined by v1.1 (Stratum 1) or RANO criteria (Stratum 2)
  • performance status ≥ 50% for participants ≥16 years of age and Lansky performance status ≥ 50% for participants \<16 years of age
  • Participants must have fully recovered from the acute toxic effects of all prior anti-cancer therapy. Participants must meet the following minimum prior to first day of study treatment:

    • Myelosuppressive chemotherapy: At least 14 days after the last dose of myelosuppressive chemotherapy
    • Radiotherapy

      • At least 14 days after local palliative XRT (small port)
      • At least 90 days must have elapsed after prior TBI, craniospinal XRT or if >50% radiation of pelvis
      • At least 42 days must have elapsed if other substantial BM radiation
      • At least 42 days must have passed since last radionuclide therapy (e.g. samarium or radium)
    • Small molecule biologic therapy: At least 7 days following the last dose of a nonmonoclonal biologic agent
    • Monoclonal antibody: At least 21 days after the last dose
    • Myeloid growth factors: At least 14 days following the last dose of long-acting growth factor (e.g. Neulasta) or 7 days following short-acting growth factor
    • Stem Cell or Autologous T Cell Infusion: At least 42 days must have elapsed after stem cell or autologous T cell infusion
  • Participants must have adequate organ function as defined below

    • Bone Marrow Function

      • ≥500/uL
      • ≥50,000/uL and transfusion independent
    • Hepatic Function

      • Total ≤ 1.5 x for age
      • (SGPT) ≤ 3 x upper limit of normal
    • Renal function

      • A serum creatinine within protocol limits based on age/sex. OR
      • ≥ 70 mL/min/1.73 m2 for participants with creatinine levels above institutional normal
    • Adequate Pulmonary Function Defined as: no evidence of dyspnea at rest, no exercise intolerance due to pulmonary insufficient and a pulse oximetry > 92% while breathing room air
    • Adequate pancreatic function defined as serum lipase ≤ ULN at baseline
    • Negative B-HCG pregnancy test in females of (must be drawn within 24 hours prior to initial administration of nivolumab)
    • Women of childbearing potential (WOCBP) receiving nivolumab agree to adhere to for a period of 5 months after the last dose of nivolumab. Men receiving nivolumab and who are sexually active with WOCBP will agree to adhere to contraception for a period of 7 months after the last dose of nivolumab.
    • Ability to understand and/or the willingness of the patient (or parent or legally authorized representative, if minor) to provide using an institutionally approved informed consent procedure.

Exclusion criteria

Exclusion Criteria:

  • Participants who are receiving any other agents.
  • Participants must not be receiving concomitant systemic medications The use of physiologic doses of corticosteroids (up to 5 mg/m2/day prednisone equivalent) may be approved after consultation with the PI (treatment with topical, inhaled or ophthalmic corticosteroid is acceptable)
  • Participants with a known history of , , and/or
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection or any other concurrent disease which in the judgment of the Investigator would make the subject inappropriate for enrollment on this study
  • Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis
  • Has active disease that has required systemic treatment in the past 12 months, or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or agents. Subjects with vitiligo or resolved childhood asthma/atopy are exceptions. Intermittent use of bronchodilators or local steroid injections are not excluded. Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. Autoimmune diagnoses not listed must be approved by the Principal Investigator.
  • Patients who have received prior solid organ transplantation are not eligible.
  • Pregnancy or Breast-Feeding. Pregnant or breast-feeding women will not be entered on this study due to risks of fetal and teratogenic adverse events as there is yet no available information regarding human fetal or teratogenic toxicities. Pregnancy tests must be obtained in girls who are post-menarchal.
  • Has received prior therapy with an , anti-PD-L1, anti-PD-L2 or anti-CTLA4 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g. OX-40, CD137)
  • Participants who have received live / attenuated vaccine within 30 days of first dose of study treatment.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Solid Tumor (Stratum 1)

    * Patients will receive combination therapy with nivolumab at a predetermined dose and ipilimumab at a predetermined dose day 1 of a 21-day cycle for 4 cycles * Starting with cycle 5, patients will receive nivolumab monotherapy at a predetermined dose on day 1 and day 15 of a 28-day cycle * Patients with INI1-negative relapsed or refractory extracranial solid tumors

    Drug: Nivolumab · Drug: Ipilimumab

  • Experimental
    CNS (Stratum 2)

    * Patients will receive combination therapy with nivolumab at a predetermined dose and ipilimumab at a predetermined dose day 1 of a 21-day cycle for 4 cycles * Starting with cycle 5, patients will receive nivolumab monotherapy at a predetermined dose on day 1 and day 15 of a 28-day cycle * Patients with INI1-negative relapsed or refractory CNS tumors

    Drug: Nivolumab · Drug: Ipilimumab

Interventions

  • Combination Therapy: Nivolumab at predetermined dosage day 1 of a 21-day cycle for 4 cycles. Monotherapy: Starting with cycle 5 nivolumab at predetermined dosage on day 1 and day 15 of a 28-day cycle

    Also known as: OPDIVO

  • Combination Therapy: Ipilimumab at predetermined dosage day 1 of a 21-day cycle for 4 cycles

    Also known as: YERYOY

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    ORR is defined as the percentage of participants who achieved a complete response (CR) or a partial response (PR), as measured by RECIST 1.1 for Stratum 1 and RANO for Stratum 2 per local assessment.

    Time frame: 12 months

Secondary outcomes

  1. Progression-free Survival (EFS) at 3 Months

    Progression-free survival (PFS) was defined as the time from study enrollment until the first occurrence of disease progression, relapse or death due to disease; patients without an event were censored at date of last disease evaluation.

    Time frame: 3 months

  2. Overall Survival (OS) at 3 Months

    OS based on the Kaplan-Meier method is defined as the time from randomization to death. Participants alive are censored at the last date of contact (including lost-to-follow-up) or at the date of withdrawal of consent, if relevant.

    Time frame: 3 months

  3. Disease Control Rate at 12 Months (DCR12)

    DCR12 is defined as the percentage of participants who are progression-free at 12 months. Progression disease (PD) is assessed using RECIST criteria for Stratum 1 and RANO criteria for Stratum 2.

    Time frame: 12 Months

07

Results

Posted Oct 20, 2026

Participant flow

Participant flow — Overall Study
MilestoneSolid Tumor (Stratum 1)CNS Tumors (Stratum 2)
Started237
Completed197
Not completed40
Withdrew: Follow up10
Withdrew: Taken off study prior to starting treatment30

Outcome measures

PrimaryObjective Response Rate (ORR)

ORR is defined as the percentage of participants who achieved a complete response (CR) or a partial response (PR), as measured by RECIST 1.1 for Stratum 1 and RANO for Stratum 2 per local assessment.

Time frame:
12 months
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR)
Percentage of participantsSolid Tumor (Stratum 1)CNS Tumors (Stratum 2)
Objective Response Rate (ORR)5 (0.1 to 25)0 (0 to 41)
SecondaryProgression-free Survival (EFS) at 3 Months

Progression-free survival (PFS) was defined as the time from study enrollment until the first occurrence of disease progression, relapse or death due to disease; patients without an event were censored at date of last disease evaluation.

Time frame:
3 months
Reported as:
Number · Percentage of participants
Progression-free Survival (EFS) at 3 Months
Percentage of participantsSolid Tumor (Stratum 1)CNS Tumors (Stratum 2)
Progression-free Survival (EFS) at 3 Months15 (4 to 33)14 (0.7 to 46)
SecondaryOverall Survival (OS) at 3 Months

OS based on the Kaplan-Meier method is defined as the time from randomization to death. Participants alive are censored at the last date of contact (including lost-to-follow-up) or at the date of withdrawal of consent, if relevant.

Time frame:
3 months
Reported as:
Number · Percentage of participants
Overall Survival (OS) at 3 Months
Percentage of participantsSolid Tumor (Stratum 1)CNS Tumors (Stratum 2)
Overall Survival (OS) at 3 Months60 (36 to 78)71 (26 to 92)
SecondaryDisease Control Rate at 12 Months (DCR12)

DCR12 is defined as the percentage of participants who are progression-free at 12 months. Progression disease (PD) is assessed using RECIST criteria for Stratum 1 and RANO criteria for Stratum 2.

Time frame:
12 Months
Reported as:
Number · percentage of participants
Disease Control Rate at 12 Months (DCR12)
percentage of participantsSolid Tumor (Stratum 1)CNS (Stratum 2)
Disease Control Rate at 12 Months (DCR12)5 (0.1 to 25)0 (0 to 41)

Adverse events

Collected over Adverse Events from enrollment to 30 days after last dose of study treatment (Treatment up to 12 months). Serious Adverse Events from enrollment to 100 days after last dose of study treatment. All-Cause Mortality up to 2 years after last dose of study treatment (Treatment up to 12 months).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Solid Tumor (Stratum 1)16/20 (80%)15/20 (75%)20/20 (100%)
CNS Tumors (Stratum 2)5/7 (71.4%)3/7 (42.9%)7/7 (100%)
Most frequent serious events
Showing 10 of 27
Most frequent serious events
EventSolid Tumor (Stratum 1)CNS Tumors (Stratum 2)
Disease progressionGeneral disorders9/202/7
HypoxiaRespiratory, thoracic and mediastinal disorders4/200/7
Pleural effusionRespiratory, thoracic and mediastinal disorders4/200/7
Abdominal painGastrointestinal disorders3/200/7
Tumor painNeoplasms benign, malignant and unspecified (incl cysts and polyps)3/200/7
VomitingGastrointestinal disorders2/201/7
HydrocephalusNervous system disorders0/201/7
SomnolenceNervous system disorders0/201/7
Nervous system disorders - Other, specifyNervous system disorders0/201/7
Surgical and medical procedures - Other, specifySurgical and medical procedures0/201/7
Most frequent other events
Showing 10 of 128
Most frequent other events
EventSolid Tumor (Stratum 1)CNS Tumors (Stratum 2)
AnemiaBlood and lymphatic system disorders13/207/7
FatigueGeneral disorders10/206/7
Lymphocyte count decreasedInvestigations16/203/7
VomitingGastrointestinal disorders6/205/7
White blood cell decreasedInvestigations8/204/7
HypertensionVascular disorders6/204/7
HypoalbuminemiaMetabolism and nutrition disorders11/201/7
HyponatremiaMetabolism and nutrition disorders11/202/7
Alanine aminotransferase increasedInvestigations4/203/7
Aspartate aminotransferase increasedInvestigations6/203/7

Baseline characteristics

This analysis only applied to participants who started study treatment, and does not included 3 participants who were enrolled on Stratum 1 and were taken off study prior to receiving any study treatment.

Age, Continuous
Age, Continuous(Years)Solid Tumor (Stratum 1)CNS Tumors (Stratum 2)Total
Mean12.4 (0.7 to 37.6)4.0 (0.6 to 8.6)7.1 (0.6 to 37.6)
Sex: Female, Male
Sex: Female, Male(Participants)Solid Tumor (Stratum 1)CNS Tumors (Stratum 2)Total
Female9312
Male11415
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Solid Tumor (Stratum 1)CNS Tumors (Stratum 2)Total
American Indian or Alaska Native000
Asian101
Native Hawaiian or Other Pacific Islander000
Black or African American202
White9110
More than one race000
Unknown or Not Reported8614
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Solid Tumor (Stratum 1)CNS Tumors (Stratum 2)Total
Hispanic or Latino123
Not Hispanic or Latino15217
Unknown or Not Reported437
08

Study locations

8 sites
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to Sponsor Investigator or designee. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data can be shared no earlier than 1 year following the date of publication

Access criteria: DFCI - Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2020 to primary completion in Jul 2025, 59 months.

Results were first posted in Oct 2026, 1 year 3 months after primary completion.

Of 23 phase 2 interventional studies under Rhabdoid Tumor, half reached primary completion within 63 months of starting (the median), counting those still running; a quarter within 52 and three quarters within 89. This study's 59 months is close to that.

Completion moved once since we started tracking on Sep 25, 2026: Jun 2026 → Jul 2027, on Oct 20, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2020
First posted
Jun 4, 2020
StartActual
Aug 14, 2020
Primary completionActual
Jul 17, 2025
CompletionEst.
Jul 1, 2027was Jun 2026
Results first posted
Oct 20, 2026
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 20, 2026
Study completion
Jun 2026→Jul 1, 2027
Oct 20, 2026
Primary outcomes
1 edited, 1 removed
What changed in the outcomes
  • EditedObjective Overall Response Rate (Stratum 1ORR)Time frame: 12 months
  • RemovedObjective Overall Response Rate (Stratum 2)Time frame: 12 months
Oct 20, 2026
Documents
Secondary outcomes
3 edited, 1 removed
What changed in the outcomes
  • EditedProgression-free survivalSurvival (PFSEFS) at 3 MonthsTime frame: 3 years → 3 months
  • EditedOverall survivalSurvival (OS) at 3 MonthsTime frame: 3 years → 3 months
  • EditedDisease control rateControl Rate at 12 monthsMonths (DCR12)Time frame: 12 Months
  • RemovedOccurrence of toxicities (Grade 3-5 per CTCAE)Time frame: 13 months
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Results posted
    Study completion Jun 2026→Jul 1, 2027
    Primary outcomes 1 edited, 1 removed
    What changed in the outcomes
    • EditedObjective Overall Response Rate (Stratum 1ORR)Time frame: 12 months
    • RemovedObjective Overall Response Rate (Stratum 2)Time frame: 12 months
    Secondary outcomes 3 edited, 1 removed
    What changed in the outcomes
    • EditedProgression-free survivalSurvival (PFSEFS) at 3 MonthsTime frame: 3 years → 3 months
    • EditedOverall survivalSurvival (OS) at 3 MonthsTime frame: 3 years → 3 months
    • EditedDisease control rateControl Rate at 12 monthsMonths (DCR12)Time frame: 12 Months
    • RemovedOccurrence of toxicities (Grade 3-5 per CTCAE)Time frame: 13 months
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04416568
Collaborators
Gateway for Cancer Research
Responsible party
Suzanne Forrest, MD (Sponsor Investigator, Dana-Farber Cancer Institute) — Principal investigator
First posted
Jun 4, 2020
Start date
Aug 14, 2020
Primary completion
Jul 17, 2025
Completion
Jul 1, 2027 (estimated)
Results posted
Oct 20, 2026
Last update
Oct 20, 2026

Study contacts

Suzanne Forrest, MD
principal investigator · Dana-Farber Cancer Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nivolumab · Ipilimumab

Start the discussion